Literature DB >> 22058418

Multiple human papillomavirus infections and type competition in men.

Anne F Rositch1, Charles Poole, Michael G Hudgens, Kawango Agot, Edith Nyagaya, Stephen Moses, Peter J F Snijders, Chris J L M Meijer, Robert C Bailey, Jennifer S Smith.   

Abstract

BACKGROUND: There is little information on multiple human papillomavirus (HPV) infections and the potential for type competition in men, yet competition may impact the type-specific efficacy of HPV vaccination.
METHODS: Among 2702 uncircumcised men in Kisumu, Kenya, who were seronegative for human immunodeficiency virus, the observed numbers of HPV types detected were compared with the expected number, which was simulated under the assumption of independent infections. To assess the potential for HPV type competition, adjusted odds ratios for pairwise combinations of prevalent HPV type infections were estimated using semi-Bayesian methods.
RESULTS: Half of all men were HPV positive, of whom 57% had multiple HPV types. We observed men without HPV infection and with ≥4 HPV types more often than expected if infections were independent. No negative associations between individual HPV types were observed. HPV types 31, 39, 56, 58, and 59 were positively associated with both carcinogenic vaccine types HPV-16 and HPV-18 (2-sided P value <.05).
CONCLUSIONS: Men who were HPV infected were likely to test positive for >1 HPV type. Cross-sectional associations between individual HPV types were positive and did not appear to be type-specific. Thus, we did not identify HPV types that are candidates for potential HPV type competition in men.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22058418      PMCID: PMC3242748          DOI: 10.1093/infdis/jir709

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

2.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

3.  Human papillomavirus infections with multiple types and risk of cervical neoplasia.

Authors:  Helen Trottier; Salaheddin Mahmud; Maria Cecilia Costa; João P Sobrinho; Eliane Duarte-Franco; Thomas E Rohan; Alex Ferenczy; Luisa L Villa; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

4.  Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections.

Authors:  Anil K Chaturvedi; Leann Myers; Ansley F Hammons; Rebecca A Clark; Kathleen Dunlap; Patricia J Kissinger; Michael E Hagensee
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-10       Impact factor: 4.254

5.  Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines.

Authors:  Fabian Mendez; Nubia Munoz; Hector Posso; Monica Molano; Victor Moreno; Adrian J C van den Brule; Margarita Ronderos; Chris Meijer; Alvaro Munoz
Journal:  J Infect Dis       Date:  2005-08-29       Impact factor: 5.226

Review 6.  Empirical-Bayes and semi-Bayes approaches to occupational and environmental hazard surveillance.

Authors:  S Greenland; C Poole
Journal:  Arch Environ Health       Date:  1994 Jan-Feb

7.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Authors:  Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr
Journal:  Lancet Oncol       Date:  2005-05       Impact factor: 41.316

8.  Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers.

Authors:  Susanne Krüger Kjaer; Christian Munk; Jeanette Falck Winther; Hans Ole Jørgensen; Chris J L M Meijer; Adriaan J C van den Brule
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-06       Impact factor: 4.254

9.  Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men.

Authors:  Martín Lajous; Nancy Mueller; Aurelio Cruz-Valdéz; Luis Victor Aguilar; Silvia Franceschi; Mauricio Hernández-Avila; Eduardo Lazcano-Ponce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

10.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

View more
  17 in total

Review 1.  Voluntary medical male circumcision: an HIV prevention priority for PEPFAR.

Authors:  Jason Bailey Reed; Emmanuel Njeuhmeli; Anne Goldzier Thomas; Melanie C Bacon; Robert Bailey; Peter Cherutich; Kelly Curran; Kim Dickson; Tim Farley; Catherine Hankins; Karin Hatzold; Jessica Justman; Zebedee Mwandi; Luke Nkinsi; Renee Ridzon; Caroline Ryan; Naomi Bock
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

2.  Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.

Authors:  Anne F Rositch; Michael G Hudgens; Danielle M Backes; Stephen Moses; Kawango Agot; Edith Nyagaya; Peter J F Snijders; Chris J L M Meijer; Robert C Bailey; Jennifer S Smith
Journal:  J Infect Dis       Date:  2012-06-18       Impact factor: 5.226

3.  Comparison of Hybribio GenoArray and Roche human papillomavirus (HPV) linear array for HPV genotyping in anal swab samples.

Authors:  Huey Chi Low; Michelle I Silver; Brandon J Brown; Chan Yoon Leng; Magaly M Blas; Patti E Gravitt; Yin Ling Woo
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

4.  Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer.

Authors:  S L Sudenga; S Shrestha
Journal:  Int J Infect Dis       Date:  2013-02-27       Impact factor: 3.623

Review 5.  HPV and anal cancer in HIV-infected individuals: a review.

Authors:  Maarten F Schim van der Loeff; Sofie H Mooij; Oliver Richel; Henry J C de Vries; Jan M Prins
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

6.  Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities.

Authors:  Markus Schmitt; Christophe Depuydt; Ina Benoy; Johannes Bogers; Jerome Antoine; Marc Arbyn; Michael Pawlita
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

7.  Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Luisa L Villa; Harriet Richardson; Ann N Burchell; François Coutlée; Eduardo L Franco
Journal:  J Infect Dis       Date:  2016-06-02       Impact factor: 5.226

8.  Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Mengzhu Jiang; Joakim Dillner; Stephen D Walter; Jay S Kaufman; François Coutlée; Luisa L Villa; Eduardo L Franco
Journal:  Am J Epidemiol       Date:  2013-05-09       Impact factor: 4.897

9.  Coinfections by noninteracting pathogens are not independent and require new tests of interaction.

Authors:  Frédéric M Hamelin; Linda J S Allen; Vrushali A Bokil; Louis J Gross; Frank M Hilker; Michael J Jeger; Carrie A Manore; Alison G Power; Megan A Rúa; Nik J Cunniffe
Journal:  PLoS Biol       Date:  2019-12-03       Impact factor: 8.029

Review 10.  Papillomaviruses: Viral evolution, cancer and evolutionary medicine.

Authors:  Ignacio G Bravo; Marta Félez-Sánchez
Journal:  Evol Med Public Health       Date:  2015-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.